Disease Landscape and Forecast Insights

Primary biliary cholangitis (PBC) is a rare autoimmune liver disease characterized by inflammation, progressive damage, and destruction of the interlobular bile ducts, followed by cholestasis,…

Primary biliary cholangitis (PBC) is a rare autoimmune liver disease characterized by inflammation and progressive damage to intrahepatic bile ducts, leading to bile buildup, followed by…

Primary biliary cholangitis (PBC) is a rare autoimmune liver disease characterized by inflammation, progressive damage, and destruction of the interlobular bile ducts; this process is followed by…

Primary biliary cholangitis (PBC) is a rare autoimmune liver disease characterized by inflammation, progressive damage, and, ultimately, destruction of the interlobular bile ducts; this process is…

Primary biliary cholangitis (PBC) is a rare autoimmune liver disease characterized by inflammation, progressive damage, and, ultimately, destruction of the interlobular bile ducts; this process is…

Clarivate Epidemiology’s coverage of primary biliary cholangitis (PBC) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States…

Primary biliary cholangitis (PBC) is a rare autoimmune liver disease characterized by inflammation, progressive damage, and, ultimately, destruction of the interlobular bile ducts; this process is…

Primary biliary cholangitis (PBC) is a rare autoimmune liver disease characterized by inflammation, progressive damage, and, ultimately, destruction of the interlobular bile ducts; this process is…

As the first agent to be approved for primary biliary cholangitis (PBC), ursodeoxycholic acid (UDCA), which launched nearly two decades ago, transformed the treatment of PBC by greatly reducing…

Primary biliary cholangitis (PBC) is a disease characterized by autoimmune destruction of small bile ducts, thereby preventing bile mobilization and increasing hepatic bile content. These symptoms…

MARKET OUTLOOK Primary sclerosing cholangitis (PSC) is a chronic, idiopathic cholangiopathy that can progress to cirrhosis, end-stage liver disease, hepatobiliary cancer, and/or colon cancer…

As the first agent to be approved for primary biliary cholangitis (PBC), ursodeoxycholic acid (UDCA) was launched nearly two decades ago and transformed the treatment of this disease by…